A Multicentre, Double-Blind, Parallel, Randomized, Placebo-Controlled Study : Evaluation of the Efficacy and Safety of Levocetirizine 5 mg and Desloratadine 5 mg Administered Orally as Capsules Once Daily, in the Morning, Over 2 Weeks in Patients Suffering From Allergic Rhinitis (AR).

Trial Profile

A Multicentre, Double-Blind, Parallel, Randomized, Placebo-Controlled Study : Evaluation of the Efficacy and Safety of Levocetirizine 5 mg and Desloratadine 5 mg Administered Orally as Capsules Once Daily, in the Morning, Over 2 Weeks in Patients Suffering From Allergic Rhinitis (AR).

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Oct 2014

At a glance

  • Drugs Levocetirizine (Primary) ; Desloratadine
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Acronyms LEADER
  • Sponsors UCB Pharma Inc
  • Most Recent Events

    • 10 Jul 2007 Status changed from in progress to completed.
    • 07 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top